2021 Autonomic Disorders Reading List, Learning Objectives, and CME

Reading List

Please click below to access the 2021 Autonomic Disorders reading list.

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

• More accurately diagnose patients with autonomic dysfunction, including postural tachycardia syndrome, inappropriate sinus tachycardia, baroreflex failure, and chronic orthostatic intolerance
• Correctly incorporate treatment modalities in the patient population which is most likely to benefit from them, including pacemaker in vasovagal syncope and treatment for stridor in multiple system atrophy
• Incorporate testing modalities to better understand the pathophysiology of underlying autonomic disorders

Core Competencies

• Medical Knowledge

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within three weeks of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 11 AMA PRA Category 1^TM credit(s). Physicians should claim only their credit commensurate with the extent of the participation in the activity.

ABPN Self-Assessment Designation Statement

The American Board of Psychiatry & Neurology (ABPN) has reviewed the UCNS Continuous Certification (C-cert) self-assessment activity and has approved the program as a part of a comprehensive self-assessment (SA) program, which is mandates by the American Board of Medical Specialties as a necessary component of maintenance of certification. The number of ABPN SA credits granted will equal the number of CME hours claimed for the activity. 

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy. 

2021 C-cert Activity Planner Disclosures
All relevant financial relationships have been mitigated.

Autonomic Disorders Certification Examination Committee Contributors

Paola Sandroni, MD, PhD, Mayo Clinic – Rochester 
Disclosures: Nothing to disclose.

Elizabeth Coon, MD, Mayo Clinic – Rochester 
Disclosures: Nothing to disclose.

Philip A. Low, MD, FAAN, Mayo Clinic – Rochester 
Disclosures: Received personal compensation from WR Medical for consultant services.

Srikanth Muppidi, MD, Stanford Neuroscience Health Center
Disclosures: Serves on advisory board for Alexion, Argenx, and ra pharma. Received royalties for "Clinical Neurophysiology Board Review Q&A", by Puneet K Gupta, Pradeep N Modur, and Srikanth Muppidi.

Peter Novak, MD, PhD, Brigham and Women's Hospital
Disclosures: Received personal compensation as Advisor - independent contractor for Dysimmune Diseases Foundation. Member of Scientific Advisory Board for Endonovo Therapeutics. Received royalties for authored book, Autonomic Testing; Holds stock in Pfizer.

Brian Olshansky, MD, University of Iowa Hospitals and Clinics
Disclosures: Received personal compensation from Boehringer Ingelheim, Lundbeck, Amarin, Sanofi-Aventis, and Respironics for consultant services.

Lauren Phillips, MD, UT Southwestern Medical School
Disclosures: Received personal compensation as a consultant for ACI Clinical - Neurology Endpoint Adjudication Committee; Received research support from NeuroNEXT (Network for Excellence in Neuroscience Clinical Trials) funded by National Institute of Health’s National Institute of Neurological Disorders and Stroke (NINDS) for project: Topirimate as a Disease Altering Therapy for role as  for Cryptogenic Sensory Peripheral Neuropathy (CSPN) [NN108 TopCSPN], role as site principal investigator; Received research support from Grifols Pharmaceuticals (Industry) for project: Dysautonomia International Title of Project: iSTAND: IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS), Role: Co-Investigator.

Satish Raj, MD, University of Calgary
Disclosures: Received compensation from Theravance Biopharma - consultant; Academy for Continued Healthcare Learning - honorarium; Arena Pharmaceuticals - DSMB Chair for Phase 2 study.

Cyndya Shibao, MD, Vanderbilt University Medical Center
Disclosures: Received speaker fee from Spire learning, educational company; Received research support from Theravance Biopharma.

Howard Snapper, MD, WellStar Medical Group
Disclosures: Received speaker fees from Akcea, Lundbeck, and Jansen.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326